Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1517 (Roxadustat) Dosing Study in Non-Dialysis CKD Anemia
NCT02964936Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of roxadustat in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Change from baseline in hemoglobin (Hb) response rate at Week 24. Started Jan 2017; status: completed.
02
Drugs
roxadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02964936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964936.